ARS Pharmaceuticals announced the immediate appointment of President Donn Casale as CEO, succeeding co-founder Richard Lowenthal, who is no longer an employee or officer effective June 6, 2026. Lowenthal co-founded the company in 2015 and led the development and commercialization of neffy, a treatment for Type 1 allergic reactions including anaphylaxis. No reason was given for his departure. Casale brings 25 years of biopharmaceutical experience, having previously served as Chief Commercial Officer at Dynavax Technologies where he oversaw the launch of the Hepatitis B vaccine HEPLISAV, and held roles at Depomed and Merck. ARS shares closed Tuesday at $8.19, down 1.68%, and slipped a further 0.73% to $8.13 in after-hours trading.
ARS Pharmaceuticals, IncCEO change with no reason given; market reaction slightly negative but impact unclear.
Merck & Company Inc
Merck KGaA